Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Finlay, Andrea K.Harris, Alex H. S
Rosenthal, Joel
Blue-Howells, Jessica
Clark, Sean
McGuire, Jim
Timko, Christine
Frayne, Susan M.
Smelson, David A.
Oliva, Elizabeth
Binswanger, Ingrid
Document Type
Journal ArticlePublication Date
2016-03-01Keywords
BuprenorphineCriminal Justice
Methadone
Opioid-related disorders
United States Department of Veterans Affairs
Community Health
Mental and Social Health
Psychiatry
Psychiatry and Psychology
Substance Abuse and Addiction
Metadata
Show full item recordAbstract
BACKGROUND: Pharmacotherapy - methadone, buprenorphine, or naltrexone - is an evidence-based treatment for opioid use disorder, but little is known about receipt of these medications among veterans involved in the justice system. The current study examines receipt of pharmacotherapy for opioid use disorder among veterans with a history of justice involvement at U.S. Veterans Health Administration (VHA) facilities compared to veterans with no justice involvement. METHODS: Using national VHA clinical and pharmacy records, we conducted a retrospective cohort study of veterans with an opioid use disorder diagnosis in fiscal year 2012. Using a mixed-effects logistic regression model, we examined receipt of pharmacotherapy in the 1-year period following diagnosis as a function of justice involvement, adjusting for patient and facility characteristics. RESULTS: The 1-year rate of receipt for pharmacotherapy for opioid use disorder was 27% for prison-involved veterans, 34% for jail/court-involved veterans, and 33% for veterans not justice-involved. Compared to veterans not justice-involved, those prison-involved had 0.75 lower adjusted odds (95% confidence interval [CI]: 0.65-0.87) of receiving pharmacotherapy whereas jail/court-involved veterans did not have significantly different adjusted odds. CONCLUSIONS: Targeted efforts to improve receipt of pharmacotherapy for opioid use disorder among veterans exiting prison is needed as they have lower odds of receiving these medications.Source
Drug Alcohol Depend. 2016 Mar 1;160:222-6. Epub 2016 Jan 24. Link to article on publisher's siteDOI
10.1016/j.drugalcdep.2016.01.013Permanent Link to this Item
http://hdl.handle.net/20.500.14038/46269PubMed ID
26832998Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.drugalcdep.2016.01.013